Share：
Share this content in WeChat
X
[Chinese][PDF]921
• Review •
Advancements and applications of magnetic resonance elastography in chronic liver diseases
JIANG Zhuoru  ZHANG Hailong  ZHU Zhengyang  ZHANG Xin  ZHANG Bing  LI Jie  CHEN Jun 

Cite this article as: JIANG Z R, ZHANG H L, ZHU Z Y, et al. Advancements and applications of magnetic resonance elastography in chronic liver diseases[J]. Chin J Magn Reson Imaging, 2025, 16(3): 190-195. DOI:10.12015/issn.1674-8034.2025.03.032.


[Abstract] Chronic liver disease exhibits a high prevalence worldwide and often progresses to liver fibrosis or cirrhosis, leading to severe complications such as liver failure and hepatocellular carcinoma. Early diagnosis and staging of liver fibrosis are crucial for the management of chronic liver disease. In recent years, magnetic resonance elastography (MRE) has emerged as a vital tool for liver fibrosis assessment due to its non-invasive nature and high accuracy. With continuous advancements in MRE technology, its application in evaluating liver fibrosis in chronic liver disease has significantly expanded. Initially, MRE was primarily used for liver fibrosis assessment in common etiologies such as viral hepatitis and metabolic dysfunction-associated fatty liver disease. However, with technological progress and increasing clinical demand, MRE has gradually been applied to a broader range of etiologies, including alcohol related-liver disease and autoimmune liver diseases. Furthermore, the application of MRE in assessing the progression of hepatitis and liver fibrosis, monitoring treatment efficacy, and predicting clinical outcomes has been extensively studied. These advancements have not only expanded the clinical utility of MRE but also provided essential imaging support for the individualized management of chronic liver diseases with diverse etiologies. Based on the different etiologies and common complications of chronic liver disease, this review summarizes the latest progress in the use of MRE for the evaluation of chronic liver disease, aiming to offer valuable insights for its clinical management.
[Keywords] magnetic resonance elastography；chronic liver diseases；liver fibrosis；mechanobiological properties

JIANG Zhuoru1, 2   ZHANG Hailong2   ZHU Zhengyang2   ZHANG Xin2   ZHANG Bing2   LI Jie1*   CHEN Jun2, 3, 4  

1 Department of Infectious Diseases, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210003, China

2 Department of Radiology, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210003, China

3 Department of Radiology, Mayo Clinic, Rochester, MN 55905, United States

4 Resoundant, Inc., Rochester, MN 55905, United States

Corresponding author: LI J, E-mail: lijier@nju.edu.cn

Conflicts of interest   None.

Received  2024-10-10
Accepted  2025-03-10
DOI: 10.12015/issn.1674-8034.2025.03.032
Cite this article as: JIANG Z R, ZHANG H L, ZHU Z Y, et al. Advancements and applications of magnetic resonance elastography in chronic liver diseases[J]. Chin J Magn Reson Imaging, 2025, 16(3): 190-195. DOI:10.12015/issn.1674-8034.2025.03.032.

[1]
GINÈS P, CASTERA L, LAMMERT F, et al. Population screening for liver fibrosis: toward early diagnosis and intervention for chronic liver diseases[J]. Hepatology, 2022, 75(1): 219-228. DOI: 10.1002/hep.32163.
[2]
ZHANG Y N, FOWLER K J, OZTURK A, et al. Liver fibrosis imaging: a clinical review of ultrasound and magnetic resonance elastography[J]. J Magn Reson Imaging, 2020, 51(1): 25-42. DOI: 10.1002/jmri.26716.
[3]
SELVARAJ E A, MÓZES F E, JAYASWAL A N A, et al. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis[J]. J Hepatol, 2021, 75(4): 770-785. DOI: 10.1016/j.jhep.2021.04.044.
[4]
HSU C, CAUSSY C, IMAJO K, et al. Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants[J]. Clin Gastroenterol Hepatol, 2019, 17(4): 630-637.e8. DOI: 10.1016/j.cgh.2018.05.059.
[5]
SIDDIQI H, HUANG D Q, MITTAL N, et al. Repeatability of vibration-controlled transient elastography versus magnetic resonance elastography in patients with cirrhosis: a prospective study[J]. Aliment Pharmacol Ther, 2024, 60(4): 484-491. DOI: 10.1111/apt.18118.
[6]
DUMAN S, KURU D, GUMUSSOY M, et al. A combination of non-invasive tests for the detection of significant fibrosis in patients with metabolic dysfunction-associated steatotic liver disease is not superior to magnetic resonance elastography alone[J]. Eur Radiol, 2024, 34(6): 3882-3888. DOI: 10.1007/s00330-023-10441-5.
[7]
SHI Y, QI Y F, LAN G Y, et al. Three-dimensional MR elastography depicts liver inflammation, fibrosis, and portal hypertension in chronic hepatitis B or C[J]. Radiology, 2021, 301(1): 154-162. DOI: 10.1148/radiol.2021202804.
[8]
WANG Y K, ZHOU J H, LIN H M, et al. Viscoelastic parameters derived from multifrequency MR elastography for depicting hepatic fibrosis and inflammation in chronic viral hepatitis[J/OL]. Insights Imaging, 2024, 15(1): 91 [2025-03-06]. https://pubmed.ncbi.nlm.nih.gov/38530543/. DOI: 10.1186/s13244-024-01652-5.
[9]
ZERUNIAN M, MASCI B, CARUSO D, et al. Liver magnetic resonance elastography: focus on methodology, technique, and feasibility[J/OL]. Diagnostics, 2024, 14(4): 379 [2025-03-06]. https://pubmed.ncbi.nlm.nih.gov/38396418/. DOI: 10.3390/diagnostics14040379.
[10]
ATAMANIUK V, HAŃCZYK Ł, CHEN J, et al. 3D vector MR elastography applications in small organs[J]. Magn Reson Imaging, 2024, 112: 54-62. DOI: 10.1016/j.mri.2024.06.005.
[11]
VAN SCHELT A S, WASSENAAR N P M, RUNGE J H, et al. Free-breathing motion corrected magnetic resonance elastography of the abdomen[J]. Quant Imaging Med Surg, 2024, 14(5): 3447-3460. DOI: 10.21037/qims-23-1727.
[12]
YANG L, ZHOU G F, LIU L H, et al. Assessing liver fibrosis in chronic liver disease: Comparison of diffusion-weighted MR elastography and two-dimensional shear-wave elastography using histopathologic assessment as the reference standard[J/OL]. Ann Hepatol, 2024, 30(1): 101743 [2025-03-06]. https://pubmed.ncbi.nlm.nih.gov/39662592/. DOI: 10.1016/j.aohep.2024.101743.
[13]
CHEN J J, SUN W, WANG W T, et al. Diffusion-based virtual MR elastography for predicting recurrence of solitary hepatocellular carcinoma after hepatectomy[J/OL]. Cancer Imaging, 2024, 24(1): 106 [2025-03-06]. https://pubmed.ncbi.nlm.nih.gov/39138500/. DOI: 10.1186/s40644-024-00759-8.
[14]
YANG L, ZHOU G, LIU L, et al. Staging chronic hepatitis B related liver fibrosis with diffusion-weighted MRI-based virtual elastography: comparisons with serum fibrosis indexes[J/OL]. Clin Radiol, 2025, 80: 106750 [2025-03-06]. https://pubmed.ncbi.nlm.nih.gov/39657563/. DOI: 10.1016/j.crad.2024.106750.
[15]
LI M K, WAN S Z, WU X Y, et al. Diagnostic performance of elastography on liver fibrosis in antiviral treatment-naive chronic hepatitis B patients: a meta-analysis[J/OL]. Gastroenterol Rep, 2022, 10(1): goac005 [2025-03-06]. https://pubmed.ncbi.nlm.nih.gov/35186298/. DOI: 10.1093/gastro/goac005.
[16]
TAMAKI N, HIGUCHI M, KEITOKU T, et al. Magnetic resonance elastography for the prediction of hepatocellular carcinoma in chronic hepatitis B[J/OL]. JGH Open, 2024, 8(4): e13067 [2025-03-06]. https://pubmed.ncbi.nlm.nih.gov/38665298/. DOI: 10.1002/jgh3.13067.
[17]
GARTEISER P, PAGÉ G, D'ASSIGNIES G, et al. Necro-inflammatory activity grading in chronic viral hepatitis with three-dimensional multifrequency MR elastography[J/OL]. Sci Rep, 2021, 11(1): 19386 [2025-03-06]. https://pubmed.ncbi.nlm.nih.gov/34588519/. DOI: 10.1038/s41598-021-98726-x.
[18]
QU Y L, MIDDLETON M S, LOOMBA R, et al. Magnetic resonance elastography biomarkers for detection of histologic alterations in nonalcoholic fatty liver disease in the absence of fibrosis[J]. Eur Radiol, 2021, 31(11): 8408-8419. DOI: 10.1007/s00330-021-07988-6.
[19]
WEI X D, QI S, WEI X H, et al. Inflammation activity affects liver stiffness measurement by magnetic resonance elastography in MASLD[J]. Dig Liver Dis, 2024, 56(10): 1715-1720. DOI: 10.1016/j.dld.2024.04.031.
[20]
IMAJO K, SAIGUSA Y, KOBAYASHI T, et al. Head-to-head comparison among FAST, MAST, and multiparametric MRI-based new score in diagnosing at-risk MASH[J/OL]. Eur Radiol, 2024 [2025-03-06]. https://pubmed.ncbi.nlm.nih.gov/39638942/. DOI: 10.1007/s00330-024-11215-3.
[21]
IMAJO K, SAIGUSA Y, KOBAYASHI T, et al. M-PAST score is better than MAST score for the diagnosis of active fibrotic nonalcoholic steatohepatitis[J]. Hepatol Res, 2023, 53(9): 844-856. DOI: 10.1111/hepr.13927.
[22]
NOUREDDIN N, AJMERA V, BERGSTROM J, et al. MEFIB-Index and MAST-Score in the assessment of hepatic decompensation in metabolic dysfunction-associated steatosis liver disease-Individual participant data meta-analyses[J]. Aliment Pharmacol Ther, 2023, 58(9): 856-865. DOI: 10.1111/apt.17707.
[23]
ALLEN A M, SHAH V H, THERNEAU T M, et al. The role of three-dimensional magnetic resonance elastography in the diagnosis of nonalcoholic steatohepatitis in obese patients undergoing bariatric surgery[J]. Hepatology, 2020, 71(2): 510-521. DOI: 10.1002/hep.30483.
[24]
LIANG J X, AMPUERO J, NIU H, et al. An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography[J]. J Hepatol, 2023, 79(3): 592-604. DOI: 10.1016/j.jhep.2023.04.025.
[25]
LIANG Y Z, LI D W. Magnetic resonance elastography in staging liver fibrosis in non-alcoholic fatty liver disease: a pooled analysis of the diagnostic accuracy[J/OL]. BMC Gastroenterol, 2020, 20(1): 89 [2025-03-06]. https://pubmed.ncbi.nlm.nih.gov/32252641/. DOI: 10.1186/s12876-020-01234-x.
[26]
LI J H, LU X, ZHU Z, et al. Head-to-head comparison of magnetic resonance elastography-based liver stiffness, fat fraction, and T1 relaxation time in identifying at-risk NASH[J]. Hepatology, 2023, 78(4): 1200-1208. DOI: 10.1097/HEP.0000000000000417.
[27]
KHALFALLAH M, DOBLAS S, HAMMOUTENE A, et al. Visco-elastic parameters at three-dimensional MR elastography for diagnosing non-alcoholic steatohepatitis and substantial fibrosis in mice[J]. J Magn Reson Imaging, 2024, 59(1): 97-107. DOI: 10.1002/jmri.28765.
[28]
TANG H Y, LI J H, ZINKER B, et al. Evaluation of a PEGylated fibroblast growth factor 21 variant using novel preclinical magnetic resonance imaging and magnetic resonance elastography in a mouse model of nonalcoholic steatohepatitis[J]. J Magn Reson Imaging, 2022, 56(3): 712-724. DOI: 10.1002/jmri.28077.
[29]
BROWN E A, MINNICH A, SANYAL A J, et al. Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial[J/OL]. JHEP Rep, 2023, 5(4): 100661 [2025-03-06]. https://pubmed.ncbi.nlm.nih.gov/36866389/. DOI: 10.1016/j.jhepr.2022.100661.
[30]
LAZARUS J V, CASTERA L, MARK H E, et al. Real-world evidence on non-invasive tests and associated cut-offs used to assess fibrosis in routine clinical practice[J/OL]. JHEP Rep, 2022, 5(1): 100596 [2025-03-06]. https://pubmed.ncbi.nlm.nih.gov/36644239/. DOI: 10.1016/j.jhepr.2022.100596.
[31]
KAWAMURA N, IMAJO K, KALUTKIEWICZ K J, et al. Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease[J]. Hepatology, 2022, 76(1): 186-195. DOI: 10.1002/hep.32302.
[32]
FOWLER K J, VENKATESH S K, OBUCHOWSKI N, et al. Repeatability of MRI biomarkers in nonalcoholic fatty liver disease: the NIMBLE consortium[J/OL]. Radiology, 2023, 309(1): e231092 [2025-03-06]. https://pubmed.ncbi.nlm.nih.gov/37815451/. DOI: 10.1148/radiol.231092.
[33]
TANG A, DZYUBAK B, YIN M, et al. MR elastography in nonalcoholic fatty liver disease: inter-center and inter-analysis-method measurement reproducibility and accuracy at 3T[J]. Eur Radiol, 2022, 32(5): 2937-2948. DOI: 10.1007/s00330-021-08381-z.
[34]
OH J H, AHN S B, CHO S, et al. Diagnostic performance of non-invasive tests in patients with MetALD in a health check-up cohort[J]. J Hepatol, 2024, 81(5): 772-780. DOI: 10.1016/j.jhep.2024.05.042.
[35]
CHEN J B, XU P, KALUTKIEWICZ K, et al. Liver stiffness measurement by magnetic resonance elastography predicts cirrhosis and decompensation in alcohol-related liver disease[J]. Abdom Radiol, 2024, 49(7): 2231-2241. DOI: 10.1007/s00261-024-04479-2.
[36]
MESROPYAN N, KUPCZYK P, DOLD L, et al. Non-invasive assessment of liver fibrosis in autoimmune hepatitis: Diagnostic value of liver magnetic resonance parametric mapping including extracellular volume fraction[J]. Abdom Radiol, 2021, 46(6): 2458-2466. DOI: 10.1007/s00261-020-02822-x.
[37]
DILLMAN J R, TROUT A T, TAYLOR A E, et al. Association between MR elastography liver stiffness and histologic liver fibrosis in children and young adults with autoimmune liver disease[J/OL]. AJR Am J Roentgenol, 2024, 223(1): e2431108 [2025-03-06]. https://pubmed.ncbi.nlm.nih.gov/38630086/. DOI: 10.2214/AJR.24.31108.
[38]
BAÑARES J, ACEITUNO L, PONS M, et al. Noninvasive assessment of portal hypertension[J]. Clin Liver Dis, 2024, 28(3): 401-415. DOI: 10.1016/j.cld.2024.03.010.
[39]
LI J H, SEHRAWAT T S, CHEN J B, et al. Quantitative assessment of portal hypertension with bi-parametric dual-frequency hepatic MR elastography in mouse models[J]. Eur Radiol, 2021, 31(4): 2303-2311. DOI: 10.1007/s00330-020-07341-3.
[40]
KENNEDY P, STOCKER D, CARBONELL G, et al. MR elastography outperforms shear wave elastography for the diagnosis of clinically significant portal hypertension[J]. Eur Radiol, 2022, 32(12): 8339-8349. DOI: 10.1007/s00330-022-08935-9.
[41]
SINGH R, WILSON M P, KATLARIWALA P, et al. Accuracy of liver and spleen stiffness on magnetic resonance elastography for detecting portal hypertension: a systematic review and meta-analysis[J]. Eur J Gastroenterol Hepatol, 2021, 32(2): 237-245. DOI: 10.1097/MEG.0000000000001724.
[42]
SERAI S D, GLENN A, TROUT A T, et al. Spleen stiffness in a healthy pediatric population undergoing liver magnetic resonance elastography[J/OL]. Pediatr Radiol, 2025 [2025-03-06]. https://pubmed.ncbi.nlm.nih.gov/39841253/. DOI: 10.1007/s00247-024-06107-z.
[43]
NAVIN P J, GIDENER T, ALLEN A M, et al. The role of magnetic resonance elastography in the diagnosis of noncirrhotic portal hypertension[J]. Clin Gastroenterol Hepatol, 2020, 18(13): 3051-3053.e2 [2025-03-06]. https://pubmed.ncbi.nlm.nih.gov/31629882/. DOI: 10.1016/j.cgh.2019.10.018.
[44]
LEE J H, HWANG J A, GU K, et al. Magnetic resonance elastography as a preoperative assessment for predicting intrahepatic recurrence in patients with hepatocellular carcinoma[J]. Magn Reson Imaging, 2024, 109: 127-133. DOI: 10.1016/j.mri.2024.03.014.
[45]
LIU G X, SHEN Z H, CHONG H H, et al. Three-dimensional multifrequency MR elastography for microvascular invasion and prognosis assessment in hepatocellular carcinoma[J]. J Magn Reson Imaging, 2024, 60(6): 2626-2640. DOI: 10.1002/jmri.29276.
[46]
LIU G X, MA D, WANG H F, et al. Three-dimensional multifrequency magnetic resonance elastography improves preoperative assessment of proliferative hepatocellular carcinoma[J/OL]. Insights Imaging, 2023, 14(1): 89 [2025-03-06]. https://pubmed.ncbi.nlm.nih.gov/37198348/. DOI: 10.1186/s13244-023-01427-4.
[47]
ZHONG L H, LONG S C, PEI Y G, et al. MRI tomoelastography to assess the combined status of vessels encapsulating tumor clusters and microvascular invasion in hepatocellular carcinoma[J/OL]. J Magn Reson Imaging, 2024 [2025-03-06]. https://pubmed.ncbi.nlm.nih.gov/39506537/. DOI: 10.1002/jmri.29654.
[48]
CHEN J, WU Z R, ZHANG Z, et al. Apparent diffusion coefficient and tissue stiffness are associated with different tumor microenvironment features of hepatocellular carcinoma[J]. Eur Radiol, 2024, 34(11): 6980-6991. DOI: 10.1007/s00330-024-10743-2.
[49]
ABE H, SHIBUTANI K, YAMAZAKI S, et al. Tumor stiffness measurement using magnetic resonance elastography can predict recurrence and survival after curative resection of hepatocellular carcinoma[J]. Surgery, 2023, 173(2): 450-456. DOI: 10.1016/j.surg.2022.11.001.
[50]
ZHANG L N, CHEN J B, JIANG H, et al. MR elastography as a biomarker for prediction of early and late recurrence in HBV-related hepatocellular carcinoma patients before hepatectomy[J/OL]. Eur J Radiol, 2022, 152: 110340 [2025-03-06]. https://pubmed.ncbi.nlm.nih.gov/39506537/. DOI: 10.1016/j.ejrad.2022.110340.
[51]
WANG J, SHAN Q G, LIU Y, et al. 3D MR elastography of hepatocellular carcinomas as a potential biomarker for predicting tumor recurrence[J]. J Magn Reson Imaging, 2019, 49(3): 719-730. DOI: 10.1002/jmri.26250.
[52]
ZHANG L N, LI M S, ZHU J, et al. The value of quantitative MR elastography-based stiffness for assessing the microvascular invasion grade in hepatocellular carcinoma[J]. Eur Radiol, 2023, 33(6): 4103-4114. DOI: 10.1007/s00330-022-09290-5.
[53]
LI M S, YIN Z Y, HU B, et al. MR elastography-based shear strain mapping for assessment of microvascular invasion in hepatocellular carcinoma[J]. Eur Radiol, 2022, 32(7): 5024-5032. DOI: 10.1007/s00330-022-08578-w.

PREV Research progress of artificial intelligence in magnetic resonance diagnosis of breast cancer
NEXT Progress on the role of magnetic resonance imaging techniques in the staged diagnosis of hepatic fibrosis
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn